A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

312 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-24

Study Completion Date

2023-03-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter, prospective, single cohort study designed to describe the natural history of DMD in Chinese male patients. A total of approximately 330 subjects will be enrolled with the target number of subjects in each group as below:

* Group 1, Ambulatory subjects aged \<6 years, approximately 100 subjects;
* Group 2, Ambulatory subjects aged \>=6 years, approximately 180 subjects;
* Group 3, Non-ambulatory subjects, approximately 50 subjects. Subjects will visit sites every 6 months. Each subject will be observed for at least 24 months. All subjects will remain enrolled until the study completion date, such that some will have data collected after Month 24. Subjects, who complete Visit 5/Month 24 at least 6 months prior to study completion, will be asked to complete an additional visit at Month 30.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Natural History of Duchenne Muscular Dystrophy

NCT03882827

Duchenne Muscular Dystrophy

UNKNOWN

A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.

NCT01753804

Duchenne Muscular Dystrophy

TERMINATED

Outcome Measures in Duchenne Muscular Dystrophy: A Natural History Study

NCT02780492

Duchenne Muscular Dystrophy

COMPLETED

Longitudinal Study of the Natural History of Duchenne Muscular Dystrophy (DMD)

NCT00468832

Duchenne Muscular Dystrophy

UNKNOWN

Prognostic Factors Affecting Duchenne Muscular Dystrophy

NCT03372655

Duchenne Muscular Dystrophy

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Duchenne Muscular Dystrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study arm

All subjects in this study will be observed for 24-30 months.

Group Type OTHER

Visit frequency

Intervention Type OTHER

All subjects need to visit sites more frequently than in routine clinical practice.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Visit frequency

All subjects need to visit sites more frequently than in routine clinical practice.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Chinese male patients with any age, diagnosed with DMD. Diagnosis must be confirmed in subject's medical history and by genetic testing obtained during routine clinical care for diagnostic purposes as reported from an appropriate regulated laboratory using a clinically validated genetic test (genetic testing is not provided by the sponsor).
2. Subjects who are \>=4 years old must be receiving glucocorticosteroids for a minimum of 6 months prior to signing informed consent. There should be no significant change (\<0.2 mg/kg) in dosage or dose regimen (not related to body weight change) for at least 3 months immediately prior to signing the informed consent. Subjects who are aged \>4 years will be exempt from this requirement; those not taking GC will be eligible if the initiation of GC treatment in these subjects is considered inappropriate in the opinion of Investigators.

Exclusion Criteria

1. Any injury which may impact functional testing. Previous injuries must be fully healed prior to consenting. Prior lower limb fractures must be fully healed and at least 3 months from injury date.
2. Presence or history of other musculoskeletal or neurologic disease or somatic disorder not related to DMD including pulmonary, cardiac, and cognitive diseases.
3. Subjects \>=4 years old who have not completed the varicella vaccination.
4. Participation in other studies involving investigational drug(s) for a minimum of 90 days prior to signing the informed consent and/or during study participation.

Minimum Eligible Age

0 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No